Uptake of radiolabelled endomorphins by experimental mammary adenocarcinoma

Nuclear Medicine Review

Volumn 8, Issue 1, 2005, Pages 1-5

  Wiercioch, Rafał ^a   Mirowski, Marek ^a   Balcerczak, Ewa ^a   Byszewska, Ewa ^b   Wierzbicki, Ryszard ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

Author keywords

opioid receptor; Endomorphin 1; Endomorphin 2; Mouse mammary adenocarcinoma

Indexed keywords

ENDOMORPHIN 1; ENDOMORPHIN 2; IODINE 125; MORPHICEPTIN; MU OPIATE RECEPTOR; POLYCLONAL ANTIBODY;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BREAST ADENOCARCINOMA; CARCINOMA CELL; CELL MEMBRANE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG TUMOR LEVEL; DRUG UPTAKE; ELECTROPHORESIS; EXPERIMENTAL NEOPLASM; FEMALE; ISOTOPE LABELING; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ANIMALS; AUTORADIOGRAPHY; CELL MEMBRANE; CROSS-LINKING REAGENTS; FEMALE; IODINE RADIOISOTOPES; KINETICS; LIGANDS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PEPTIDES; PROTEIN BINDING; RECEPTORS, OPIOID, MU; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 21444454877     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Fimiani C, Arcuri E, Santoni A, Rialas CM, Bilfinger TV, Peter D, Salzet B, Stefano GB. μ3 opiate receptor expression in lung and lung carcinoma: ligand binding and coupling to nitric oxide release. Cancer Letters 1999; 146: 45-51.
2. Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci USA 1990; 87: 3294-3298.
3. Maneckjee R, Biswas R, Vonderhaar BK. Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res 1990; 50: 2234-2238.
4. Bohn LM, Belcheva MM, Coscia CJ. Evidence for κ- and μ-opioid receptor expression in C6 glioma cells. J Neurochemistry 1998; 70: 1819-1825.
5. Ard MD, Goldstein MN, Nash DR., Gottlieb DL. NMB: a human neuroblastoma cell line with specific opiate binding sites. Biochem Biophys Res Commun 1985; 133: 60-66.
6. Kampa M, Bakogeorgu E, Hatzoglou A, Damianaki A, Martin PM, Castanas E. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur J Pharmacol 1997; 335: 255-265.
7. Hatzoglou A, Bakogeorgou E, Hatzoglou C, Martin PM, Castanas E. Antiproliferative and receptor binding properties of alpha- and beta-casomorphins in the T47D human breast cancer cell line. Eur J Pharmacol 1996; 310: 217-223.
8. Mirowski M, Wiercioch R, Janecka A et al. Uptake of radiolabelled morphiceptin and its analogues by experimental mammary adenocarcinoma: in vivo and in vitro studies. Nucl. Med Biol. 2004; 31: 451-457.
9. Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the μ-opiate receptor, Nature 1997; 386: 499-502.
10. Hackler L, Zadina JE, Ge LJ, Kastin AJ. Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides 1997; 18: 1635-1639.
11. Przewlocki R, Labuz D, Mika J, Przewlocka B, Tomboly C, Toth G. Pain inhibition by endomorphins. Ann NY Acad Sci 1999; 897: 152-156.
12. Asakawa A, Inui A, Momose K, Ueno N, Fujino MA, Kasuga M. Endomorphin-1, an endogenous μ-opioid receptor-selective agonist, stimulates oxygen consumption in mice. Horm Metab Res 2000; 32: 51-52.
13. Kwok EH, Dun NJ. Endomorphins decrease heart rate and blood pressure possibly by activating vagal afferents in anesthetized rats. Brain Res 1998; 803: 204-207.
14. Hatzoglou A, Ouafik L, Bakogeorgou E, Thermos K, Castanas E. Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line and decreases cell growth. Cancer Res 1995; 23: 5632-5636.
15. 131I-labelled human growth hormones of high specific radioactivity. Biochem J 1963; 89: 114-123.
16. Mirowski M, Świtalska J, Wiercioch R, Byszewska E, Niewiadomska H, Michalska M. Uptake of radiolabelled alpha-fetoprotein (AFP) by experimental mammary adenocarcinoma and adenoma: in vivo and in vitro studies. Nucl Med Commun 2003; 24: 297-303.
17. Zagon I, McLaughlin P, Goodman S, Ehodes R. Opiod receptors and endogenous opioids in diverse human and animal cancers. J Natl Cancer Inst 1987; 79: 1059-1065.
18. Scopsi L, Balslev E, Brunner N, Poulsen HS, Andersen J, Rank F, Larsson LI. Immunoreactive opioid peptides in human breast cancer. Am J Pathol 1989; 134: 473-479.
19. Halldin C, Gulyas B, Langer O, Farde I. Brain radioligands - state of the art and new trends. Q J Nucl Med 2001; 45: 139-152.
20. Brantl V, Teschemacher H, Henschen A, Lottspeich F. Novel opioid peptides derived from casein (β-casomorphins). I. Isolation from bovine casein peptone. Hoppe Seylers Z Physiol Chem 1979; 360: 1211-1216.
21. 2): a potent and specific agonist for morphine (μ) receptors. Science 1981; 121: 75-77.
22. Prevost G, Provost P, Salle V, Lanson M, Thomas F. A cross-linking assay allows the detection of receptors for the somatostatin analogue, lanreotide in human breast tumours. Eur J Cancer 1993; 29A: 1589-1592.
23. 3H]funaltrexamine-labelled mu-opioid receptors: species variations in molecular mass and glycosylation by complex-type, N-linked oligosaccharides. Mol Pharmacol 1993; 44: 749-756.
24. Goldberg IE, Rossi GC, Letchworth SR, Mathis JP, Ryan-Mord J, Leventhal L, Su W, Emmel D, Bolan EA, Pasternak GW. Pharmacological characterization of Endomorphin-1 and Endomorphin-2 in mouse brain. J Pharm Exp Ther 1998; 286: 1007-1013.
25. Fichna J, Krajewska U, Rózalski M, Mirowski M, Janecka A. Characterization of the [125I] endomorphin-2 binding sites in the MCF7 breast cancer cell line. Peptides 2005; 26: 395-399.